Author + information
- Perwaiz M. Meraj,
- Rajkumar Doshi,
- Amitkumar Patel,
- Bhavitha George and
- Rajiv Jauhar
Background: Background: Transradial access (TRA) for percutaneous coronary intervention (PCI) has been shown to be associated with better outcomes when compared to femoral access. However, it is not clear if bivalirudin maintains its benefit over unfractionated heparin (UFH) for patients with acute coronary syndrome (ACS) patients when utilizing RA.
Methods: 6474 patients were identified from our multicenter registry who underwent PCI using TRA from January 2011-April 2016. The primary safety outcome was bleeding within 72 hours while primary efficacy outcome was death at discharge. All data was prospectively obtained and retrospectively analyzed.
Results: Primary efficacy outcomes were not significantly different between the two groups. Myocardial infarction, RBC transfusion and bleeding within 72 hours were significantly lower with UFH as compared with bivalirudin for ACS patients.
Conclusions: In an era where TRA is becoming more ubiquitous, the utilization of bivalirudin remains questionable as many studies are demonstrating that the benefit has waned. This real world, all comer multicenter study for patients in ACS demonstrates that even in this high risk population, UFH is at least equivalent if not superior to bivalirudin.
Poster Hall, Hall C
Sunday, March 19, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Optimizing the Care of ACS Patients
Abstract Category: 15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology
Presentation Number: 1284-155
- 2017 American College of Cardiology Foundation